The estimated Net Worth of David E.Activist Investing ... is at least 23.7 百万$ dollars as of 24 January 2023. David Investing owns over 57,500 units of Titan Pharmaceuticals, (de) stock worth over 19,079,518$ and over the last 2 years David sold TTNP stock worth over 4,610,001$.
David has made over 3 trades of the Titan Pharmaceuticals, (de) stock since 2022, according to the Form 4 filled with the SEC. Most recently David sold 3,747,968 units of TTNP stock worth 4,610,001$ on 21 June 2023.
The largest trade David's ever made was selling 3,747,968 units of Titan Pharmaceuticals, (de) stock on 21 June 2023 worth over 4,610,001$. On average, David trades about 2,010,553 units every 117 days since 2022. As of 24 January 2023 David still owns at least 3,388,902 units of Titan Pharmaceuticals, (de) stock.
You can see the complete history of David Investing stock trades at the bottom of the page.
Over the last 9 years, insiders at Titan Pharmaceuticals, (de) have traded over 4,610,001$ worth of Titan Pharmaceuticals, (de) stock and bought 3,252,657 units worth 2,558,794$ . The most active insiders traders include David E.Activist Investing ...、James R Mcnab、Marc Rubin. On average, Titan Pharmaceuticals, (de) executives and independent directors trade stock every 204 days with the average trade being worth of 2,815,253$. The most recent stock trade was executed by David E.Activist Investing ... on 21 June 2023, trading 3,747,968 units of TTNP stock currently worth 4,610,001$.
titan pharmaceuticals inc. is developing proprietary therapeutics primarily for the treatment of serious medical disorders. the company's lead product is probuphine®, the first and only commercialized treatment of opioid dependence to provide continuous, around-the-clock blood levels of buprenorphine for six months following a single procedure. it was approved by the u.s. food and drug administration in may 2016 and is being commercialized in the u.s. by partner braeburn pharmaceuticals. probuphine employs titan's proprietary drug delivery system proneura™, which is capable of delivering sustained, consistent levels of medication for up to 12 months. the proneura technology has the potential to be used in developing products for treating other chronic conditions such as parkinson's disease and hypothyroidism, where maintaining consistent, around-the-clock blood levels of medication may benefit the patient and improve medical outcomes.
Titan Pharmaceuticals, (de) executives and other stock owners filed with the SEC include: